XTL Biopharmaceuticals Price to Free Cash Flow Ratio 2010-2024 | XTLB

XTL Biopharmaceuticals price to free cash flow ratio from 2010 to 2024. Price to free cash flow ratio can be defined as

XTL Biopharmaceuticals Price to Free Cash Flow Ratio 2010-2024 | XTLB

XTL Biopharmaceuticals price to free cash flow ratio from 2010 to 2024. Price to free cash flow ratio can be defined as
Related Stocks
Company NameMarket
Cap
Chugai Pharmaceutical (CHGCY)$81.7B
Zoetis (ZTS)$66.3B
Daiichi Sankyo, - (DSNKY)$46.4B
Takeda Pharmaceutical (TAK)$43.3B
BeOne Medicines - (ONC)$32.9B
Sandoz Group AG (SDZNY)$25.9B
Summit Therapeutics (SMMT)$19.8B
Merck (MKKGY)$16.5B
Shionogi (SGIOY)$14.3B
Neurocrine Biosciences (NBIX)$13.5B
United Therapeutics (UTHR)$12.7B
Orion OYJ (ORINY)$11.5B
IPSEN (IPSEY)$10.8B
Stevanato Group S.p.A (STVN)$7.6B
Grifols, S.A (GRFS)$7.5B
Corcept Therapeutics (CORT)$7.4B
Ionis Pharmaceuticals (IONS)$6.9B
Madrigal Pharmaceuticals (MDGL)$6.4B
Hikma Pharmaceuticals Plc (HKMPF)$5.9B
Ono Pharmaceutical (OPHLF)$5.2B
Soleno Therapeutics (SLNO)$4.3B
Hypermarcas (HYPMY)$3.1B
Crinetics Pharmaceuticals (CRNX)$2.7B
Catalyst Pharmaceuticals (CPRX)$2.6B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.5B
NewAmsterdam Pharma (NAMS)$2.5B
Centessa Pharmaceuticals (CNTA)$2.2B
Ocular Therapeutix (OCUL)$1.9B
Endo (NDOI)$1.8B
ARS Pharmaceuticals (SPRY)$1.8B